On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator’s choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United States, where overall survival was the sole primary endpoint, the trial failed to demonstrate a statistically significant improvement, missing its primary endpoint. While the drug maintains its accelerated FDA approval, the missing survival endpoint forces both companies to review the full data set with regulators to figure out the path forward.
Genmab A/S (NASDAQ:GMAB) vs. AbbVie Inc. (NYSE:ABBV): Financial Strength & Head-to-Head Comparison
While both companies partner on epcoritamab, their financial profiles operate on entirely different scales.
Genmab released its first-half (H1) 2026 results in early August, generating total revenue of $2.051 billion, a 25% year-over-year increase from $1.640 billion in H1 2025. Growth was anchored by royalty revenues of $1.708 billion (up 24%), propelled by J&J’s DARZALEX net sales reaching $8.171 billion (up 21%) alongside strong Kesimpta royalties. Global net sales for EPKINLY/TEPKINLY jumped 48% to $312 million. Adjusted operating profit reached $656 million (up from $554 million in H1 2025). Backed by surging royalties and EPKINLY demand, Genmab raised its full-year 2026 revenue guidance to $4.325–$4.525 billion (midpoint $4.425 billion) and adjusted operating profit to $1.065–$1.385 billion. Wall Street responded positively: on August 7, Guggenheim analyst Michael Schmidt raised Genmab’s price target to $42 from $40 with a Buy rating, citing “robust” execution and improved guidance.
AbbVie delivered a massive Q2 2026 report on July 31, generating $16.99 billion in net revenues (up 10.2% year-over-year) and adjusted diluted EPS of $3.65 (up 22.9%). Robust growth was driven by its blockbuster immunology portfolio ($8.79 billion, up 15.1%), where Skyrizi and Rinvoq combined for over $8 billion in sales, effortlessly absorbing ongoing Humira declines. Neuroscience also jumped 20.3% to $3.23 billion. On August 5, Erste Group upgraded AbbVie from Hold to Buy, pointing to pipeline progress across immunology, neuroscience, and oncology, alongside a slight raise in AbbVie’s revenue forecast. AbbVie also expanded its pipeline beyond therapeutics; the FDA recently, on August 4, accepted its sBLA for Botox Cosmetic to treat masseter muscle prominence (jawline slimming).
In financial terms, AbbVie is the superior mega-cap play. It generates massive diversified cash flows that shield it from single-trial setbacks, whereas pure-play biotech Genmab offers higher growth velocity but carries greater pipeline concentration risk.
Bull and Bear Cases
Genmab’s bull case centers on the accelerating adoption of proprietary drugs such as EPKINLY and Tivdak, which could drive high-margin revenue growth. The company’s raised 2026 guidance further supports expectations for durable royalty expansion and increasing commercial scale. However, the bear case stems from the EPCORE DLBCL-1 overall survival failure, which creates regulatory uncertainty around full U.S. approval. Genmab’s pipeline concentration also leaves its shares vulnerable to volatility surrounding clinical trial readouts.
For AbbVie, the bull case is supported by Skyrizi and Rinvoq successfully replacing Humira as key revenue growth drivers. The company’s deep pipeline across neuroscience, oncology, and aesthetics also provides diversified sources of potential income growth. On the downside, regulatory setbacks involving co-developed oncology drugs could slow AbbVie’s expansion into blood cancers. In addition, declining sales of older assets such as Imbruvica, which fell 29.4%, continue to weigh on oncology revenue and could offset some of the growth generated by newer therapies.
Insider Monkey Hedge Fund Data Analysis
Institutional interest diverged slightly heading into 2026. Genmab A/S (NASDAQ:GMAB) saw hedge fund sentiment tick upward in Q1 2026, reaching 24 funds holding shares compared to 20 in Q4 2025. Notable buyers included Will England’s Walleye Capital, which held 44,300 shares ($1.22M value, up 53%), and David Harding’s Winton Capital Management, which increased its position by 159% to 40,900 shares ($1.12M value).
AbbVie Inc. (NYSE:ABBV) maintained far larger institutional ownership, held by 87 hedge funds in Q1 2026, up from 84 in Q4 2025. Position sizes remained heavy, led by Ken Fisher’s Fisher Asset Management with 9.50 million shares valued at $2.39 billion (up 5%), and Lee Munder Capital Group holding 139,806 shares valued at $35.18 million (up 3%).
Conclusion & What to Watch
The trial endpoint clarification highlights a key lesson for healthcare investors: single clinical trial setbacks affect companies differently based on their scale. For Genmab, regulatory discussions regarding the complete EPCORE data set are critical to defending its valuation. For AbbVie, the failure is easily absorbed by its massive immunology engine. Investors should monitor FDA feedback on epcoritamab’s conversion to full approval, as well as AbbVie’s execution on label expansions like Botox Cosmetic for masseter prominence.
While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
